source
- Astellas partners with AI Proteins on $400M computational drug discovery dealAstellas Pharma of Japan has entered a partnership with Boston based AI Proteins to apply its computational design platform to drug discovery. AI Proteins builds miniproteins from scratch using ar…
- Mark Cuban's Cost Plus Drugs targets rare disease market with custom n-of-1 therapiesMark Cuban's Cost Plus Drugs, known for low-cost generics, is expanding into rare disease treatments. The company has dedicated part of its new manufacturing plant to producing custom "n-of-1" the…